(EMAILWIRE.COM, February 12, 2019 ) The overactive bladder treatment market includes various therapies, namely, anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence. The global market is projected to be valued at USD 3.63 Billion in 2017 and is expected to grow at a CAGR of 2.9% during the forecast period to reach to USD 4.19 Billion by 2022. Base year considered for the report is 2016. The development of innovative intravesical therapies, aggressive marketing by pharma companies, and favorable demographics are the key factors driving the growth of the market.

Therapy approvals are regulated by various regional regulatory authorities. The changing regulatory scenario favoring overactive bladder treatments in a number of countries, such as the U.K. and Japan, will offer significant growth opportunities for market players. For example, the U.K.’s National Institutes for Health and Care Excellence (NICE) reimburses the BOTOX therapy. In 2007, the Japanese Ministry of Health, Labour and Welfare (MHLW) launched an action plan to promote the safe use of generics.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219938791

Geographically, the global market is segmented into the U.S., Europe, Asia-Pacific, and the Rest of the World. In 2016, the U.S. dominated the market and this is primarily attributed to its well-established healthcare industry with favorable reimbursement of overactive bladder treatment, growing prevalence of the disease with rising age, and the presence of major players. The Rest of Asia-Pacific region is expected to witness the highest CAGR during the forecast period owing to rising prevalence of bladder overactivity, increasing geriatric population, rising healthcare expenditure, and growing awareness on overactive bladder.

In 2016, Astellas Pharma, Inc. (Japan) and Pfizer, Inc. (U.S.) dominated the global market. Some of the other players competing in market are Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (U.S.), Endo International Plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan), Sanofi (France), Aurobindo Pharma Limited (India), Apotex, Inc. (Canada), and Cogentix Medical, Inc. (U.S.).

Know More: https://www.marketsandmarkets.com/Market-Reports/overactive-bladder-treatment-market-219938791.html